Pravastatin
FDA Approved
Description
Pravastatin is an HMG-CoA reductase inhibitor used primarily for hypercholesterolemia. It has been studied in Fish-eye disease, a rare genetic disorder characterized by severe HDL deficiency and corneal opacities. The drug helps manage lipid abnormalities associated with LCAT deficiency disorders.
Indications & Therapeutic Use
Hypercholesterolemia, dyslipidemia, Fish-eye disease (off-label)
Linked Diseases:
Fish-eye disease
C538467
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pravastatin
| Generic Name | Pravastatin |
| Brands | 1 brand available |
| Active Ingredient | Pravastatin sodium |
| Drug Class | Hypercholesterolemia |
| Manufacturer | Bristol-Myers Squibb |
| Dosage Forms | Oral tablet, 10mg, 20mg, 40mg, 80mg |
| Medical Code | C10AA03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes